Published in AIDS on May 15, 2017
Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. J Acquir Immune Defic Syndr (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (2015) 9.40
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 5.59
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med (2016) 3.82
Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One (2014) 2.85
The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care (2008) 1.97
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav (2013) 1.72
Social networks, ideation, and contraceptive behavior in Bangladesh: a longitudinal analysis. Soc Sci Med (2000) 1.57
Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS (2012) 1.55
Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PLoS One (2010) 1.54
Re-framing microbicide acceptability: findings from the MDP301 trial. Cult Health Sex (2010) 1.51
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 1.36
Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav (2012) 1.35
High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav (2012) 1.30
Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J Womens Health (Larchmt) (2011) 1.22
The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav (2011) 1.10
Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav (2009) 1.08
Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. PLoS One (2015) 1.03
"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav (2014) 1.00
Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc (2014) 0.99
Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS (2015) 0.96
Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding". AIDS Behav (2015) 0.95
A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. J Int AIDS Soc (2014) 0.93
An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc (2010) 0.92
Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa. PLoS One (2016) 0.91
Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. J Acquir Immune Defic Syndr (2016) 0.87
Adolescent experiences with the vaginal ring. J Adolesc Health (2008) 0.87
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis (2007) 4.12
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
Early age of first sex: a risk factor for HIV infection among women in Zimbabwe. AIDS (2004) 3.30
Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav (2009) 3.29
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS (2008) 2.96
Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85
Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS (2004) 2.78
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep (2011) 2.72
Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis (2006) 2.68
Vaginal washing and increased risk of HIV-1 acquisition among African women: a 10-year prospective study. AIDS (2006) 2.67
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol (2009) 2.57
Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One (2012) 2.53
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health (2009) 2.48
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clin Infect Dis (2008) 2.42
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
The impact of early monitored management on survival in hospitalized adult Ugandan patients with severe sepsis: a prospective intervention study*. Crit Care Med (2012) 2.29
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (2005) 2.28
Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata. J Acquir Immune Defic Syndr (2011) 2.27
Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med (2010) 2.26
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis (2008) 2.21
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr (2011) 2.16
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med (2012) 2.06
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS (2012) 2.02
Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr (2010) 2.01
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa. J Adolesc Health (2008) 1.97
High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr (2013) 1.97
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis (2012) 1.97
Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med (2011) 1.89
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr (2012) 1.84
HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep (2012) 1.83
Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis (2011) 1.83
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
HIV risk and associations of HIV infection among men who have sex with men in peri-urban Cape Town, South Africa. BMC Public Health (2011) 1.79
Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV (2015) 1.77
Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters. J Infect Dis (2013) 1.74
Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment. S Afr Med J (2011) 1.74
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav (2013) 1.72
Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J Adolesc Health (2006) 1.71
Tuberculosis control has failed in South Africa--time to reappraise strategy. S Afr Med J (2011) 1.70
Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr (2011) 1.69
Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet (2012) 1.65
Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One (2011) 1.63